Skip to main content
Assets
Medtronic logo
MDT.NYSE
Medtronic
Health Care · Health Care Equipment

Medical technology company providing devices, services, and therapies across cardiovascular, surgical, neuroscience, and diabetes care.

HQ: IrelandListed: United States

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for Medtronic.

Historical AI Forecasts

Medtronic plc (MDT.NYSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts

AI Advisor 1 AI

Independent Investor FrameworkAI Researcher

Model rating

Buy

5-Year Return Est.

+63.8%

Includes 2.17% annual net dividend contribution

1. Investment Thesis — Base Case

The most reasonable thesis projects Medtronic as a steady 'mid-single-digit' revenue grower with improving profitability. The successful 2024-2025 rollout of dual PFA technologies (Affera/PulseSelect) establishes Medtronic as a leader in the cardiac ablation revolution, offsetting slower growth in legacy pacing. The strategic pivot in Diabetes—outsourcing sensor tech to Abbott (Instinct CGM) while focusing on MDT's superior pump algorithms—successfully stabilizes the unit and returns it to growth. initiatives initiated in FY24/25 begin to structurally improve margins, counteracting inflationary pressures. While Hugo robotics offers optionality, the core thesis relies on the reliable execution of the cardiovascular and neuroscience portfolios. The stock likely compounds at a steady 8-10% annual rate (including dividends), driven by earnings growth and modest valuation expansion to ~18-20x P/E, reflecting its status as a high-quality defensive .

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.61.7287.04112.35137.67162.99Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (USD)
Observed price2020-11-23114
Observed price2020-12-06111
Observed price2020-12-15115
Observed price2020-12-24114
Observed price2021-01-10119
Observed price2021-01-27111
Observed price2021-02-09118
Observed price2021-03-16119
Observed price2021-03-20116
Observed price2021-03-25117
Observed price2021-04-20128
Observed price2021-04-28131
Observed price2021-05-11125
Observed price2021-05-24127
Observed price2021-06-02124
Observed price2021-06-28124
Observed price2021-07-11128
Observed price2021-08-02131
Observed price2021-08-10126
Observed price2021-09-05134
Observed price2021-09-18129
Observed price2021-09-23129
Observed price2021-10-19121
Observed price2021-10-23123
Observed price2021-11-18117
Observed price2021-11-22115
Observed price2021-12-18102
Observed price2021-12-22103
Observed price2022-01-13109
Observed price2022-01-22105
Observed price2022-02-04103
Observed price2022-02-21104
Observed price2022-03-19109
Observed price2022-03-23107
Observed price2022-04-10112
Observed price2022-04-23108
Observed price2022-05-10101
Observed price2022-05-23103
Observed price2022-06-1888.3
Observed price2022-06-2288.7
Observed price2022-07-0191.2
Observed price2022-07-2390.2
Observed price2022-08-1895.1
Observed price2022-08-2290.7
Observed price2022-09-0486.6
Observed price2022-09-3081.2
Observed price2022-10-0484.9
Observed price2022-10-3087.3
Observed price2022-11-0880.7
Observed price2022-11-2181.9
Observed price2022-12-1776.8
Observed price2022-12-2177.2
Observed price2023-01-1280.3
Observed price2023-01-2180.0
Observed price2023-02-0385.6
Observed price2023-02-2084.3
Observed price2023-03-0978.3
Observed price2023-03-2779.2
Observed price2023-04-1782.4
Observed price2023-04-2286.0
Observed price2023-04-3090.8
Observed price2023-05-3082.9
Observed price2023-06-1788.3
Observed price2023-06-2188.1
Observed price2023-07-0886.5
Observed price2023-07-2690.2
Observed price2023-08-1681.6
Observed price2023-08-2982.1
Observed price2023-09-0780.1
Observed price2023-09-2081.3
Observed price2023-10-1671.9
Observed price2023-10-2970.2
Observed price2023-11-1574.0
Observed price2023-11-2077.1
Observed price2023-12-1682.8
Observed price2023-12-2082.0
Observed price2024-01-1187.1
Observed price2024-02-0187.6
Observed price2024-02-1484.7
Observed price2024-02-1985.5
Observed price2024-02-2783.5
Observed price2024-04-0285.5
Observed price2024-04-1579.4
Observed price2024-04-2479.6
Observed price2024-05-1585.5
Observed price2024-05-2085.3
Observed price2024-06-1580.8
Observed price2024-06-1981.0
Observed price2024-07-1177.1
Observed price2024-07-2479.1
Observed price2024-08-1483.6
Observed price2024-08-1986.4
Observed price2024-09-0590.9
Observed price2024-10-0588.0
Observed price2024-10-1489.8
Observed price2024-10-2391.0
Observed price2024-11-1386.2
Observed price2024-11-2686.3
Observed price2024-12-1382.0
Observed price2024-12-3180.1
Observed price2025-01-1385.0
Observed price2025-01-1788.2
Observed price2025-02-1292.0
Observed price2025-02-2188.5
Observed price2025-03-0694.1
Observed price2025-03-1991.7
Observed price2025-04-1482.4
Observed price2025-04-1882.0
Observed price2025-05-1486.1
Observed price2025-05-2380.7
Observed price2025-06-1388.0
Observed price2025-06-2686.0
Observed price2025-07-1489.7
Observed price2025-08-0490.1
Observed price2025-08-1392.6
Observed price2025-08-2692.0
Observed price2025-09-1294.2
Observed price2025-09-2594.2
Observed price2025-10-0496.9
Observed price2025-10-1795.6
Observed price2025-11-0390.5
Observed price2025-11-25105
Observed price2025-12-1299.5
Observed price2025-12-3096.1
Observed price2026-01-0799.3
Observed price2026-01-1699.3
Observed price2026-02-02103
Observed price2026-02-2897.7
Observed price2026-03-1387.2
Observed price2026-04-0486.4
Observed price2026-04-1388.1
Observed price2026-04-1786.0
Observed price2026-05-0976.2
Observed price2026-05-3074.5
Observed price2026-06-0882.0
Observed price2026-06-1778.1
Observed price2026-07-1283.6
Observed price2026-07-2182.0
Observed price2026-08-1290.7
Observed price2026-08-1690.7
Observed price2026-09-1493.8
Observed price2026-09-1593.8
Observed price2026-09-1892.1
Published advisor forecast2025-11-26105
Published advisor forecast2026-05-27110
Published advisor forecast2026-11-27114
Published advisor forecast2027-05-27120
Published advisor forecast2027-11-27124
Published advisor forecast2028-05-27130
Published advisor forecast2028-11-27134
Published advisor forecast2029-05-27139
Published advisor forecast2029-11-27145
Published advisor forecast2030-05-27149
Published advisor forecast2030-11-27155

2. Scenarios & Signals

Bull case

In a bullish scenario, Medtronic's 'comprehensive transformation' yields superior operational leverage, pushing above 30%. The cardiovascular portfolio dominates the Pulsed Field Ablation (PFA) super-cycle with the Affera and PulseSelect systems creating a defensible moat against Boston Scientific. Crucially, the diabetes segment achieves double-digit growth as the partnership with Abbott for the Instinct CGM integration eliminates the sensor gap, allowing the MiniMed 780G to capture significant from competitors. The Hugo RAS (robotic-assisted surgery) system receives timely US FDA clearance and gains rapid adoption in urology and gynecology, disrupting the Intuitive Surgical monopoly. Macro-economically, a weakening USD boosts reported earnings, and fading headwinds restore investor confidence in long-term procedural volumes. Valuation multiples expand to ~22-24x P/E as MDT re-rates as a growth .

Bear case

In a bearish scenario, the ' effect' proves more detrimental than anticipated, showing tangible reductions in bariatric and cardiovascular procedural volumes, compressing the (). The launch of the Hugo robotics system in the US faces regulatory delays or fails to gain traction against an entrenched Da Vinci ecosystem. In the cardiac space, pricing pressure from competitors in the PFA market erodes margins despite volume growth. Geopolitically, expanded Volume-Based Procurement (VBP) policies in China aggressively target Medtronic's high-margin legacy staples, while persistent inflation keeps costs elevated. The integration with Abbott's sensors faces technical hurdles or fails to win back disillusioned patients. Consequently, earnings stagnation leads to toward 12-14x P/E, causing the stock to drift lower toward the $80s.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus